The global cutting angioplasty balloons market is witnessing steady growth as healthcare providers increasingly adopt advanced minimally invasive technologies for the treatment of cardiovascular diseases. Valued at US$ 205.9 million in 2022, the market is projected to expand at a CAGR of 6.4% from 2023 to 2031 and exceed US$ 360.0 million by the end of the forecast period.

The growing prevalence of cardiovascular diseases (CVDs), rising geriatric population, and continuous technological advancements in angioplasty devices are among the primary factors driving market expansion. As healthcare systems worldwide focus on improving patient outcomes and reducing procedural complications, cutting angioplasty balloons are becoming an essential tool in the treatment of complex arterial blockages.

Understanding Cutting Angioplasty Balloons

Cutting angioplasty balloons are specialized catheter-based devices used to treat narrowed or blocked arteries caused by plaque accumulation. Unlike conventional angioplasty balloons, these devices feature tiny microsurgical blades mounted on the balloon surface. When inflated, the blades create controlled incisions in the plaque, enabling more effective dilation of the artery while minimizing damage to the vessel wall.

These balloons are particularly useful in complex coronary lesions where traditional balloon angioplasty may be less effective. Their ability to precisely modify plaque reduces the risk of arterial dissection and improves long-term treatment outcomes. As a result, cutting angioplasty balloons have gained widespread acceptance among interventional cardiologists and vascular specialists.

Growing Cardiovascular Disease Burden Driving Market Demand

The increasing incidence of cardiovascular diseases remains the most significant factor fueling demand for cutting angioplasty balloons. Conditions such as coronary artery disease, peripheral artery disease, heart failure, and stroke continue to place a substantial burden on healthcare systems worldwide.

According to global health statistics, cardiovascular diseases account for approximately 31% of all deaths worldwide, causing nearly 17.9 million deaths annually. Factors such as aging populations, sedentary lifestyles, obesity, smoking, diabetes, and unhealthy dietary habits continue to contribute to the rising prevalence of these conditions.

Coronary artery disease, in particular, represents one of the most common applications for cutting angioplasty balloons. The technology enables physicians to effectively open blocked arteries, restore blood flow, and reduce the risk of life-threatening cardiac events. Consequently, increasing cardiovascular disease cases are expected to create significant growth opportunities for market participants throughout the forecast period.

Technological Innovations Enhancing Treatment Outcomes

Continuous innovation in balloon catheter technology is transforming the cutting angioplasty balloons market. Manufacturers are investing heavily in research and development to improve device flexibility, durability, deliverability, and procedural precision.

One of the most significant advancements is the introduction of drug-coated cutting balloons. These devices combine plaque-modifying capabilities with targeted drug delivery, helping prevent restenosis or re-narrowing of the treated artery. By delivering therapeutic agents directly to the lesion site, drug-coated cutting balloons reduce the likelihood of repeat procedures and improve long-term patient outcomes.

Advanced imaging technologies such as Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT) are also being integrated into treatment workflows. These imaging modalities allow physicians to visualize arterial structures in greater detail, improving procedural accuracy and enhancing treatment effectiveness.

Drug-coated Cutting Balloons Leading Product Segment Growth

Among product categories, drug-coated cutting balloons are expected to dominate the market during the forecast period. Their ability to simultaneously modify plaque and deliver anti-restenotic medications has positioned them as a preferred treatment option for complex vascular interventions.

The growing adoption of these advanced devices is supported by favorable clinical outcomes, reduced need for stent implantation, faster patient recovery, and lower risk of repeat interventions. Continuous advancements in coating technologies and drug formulations are further strengthening the segment's growth prospects.

Conventional cutting balloons and scoring balloons continue to maintain their relevance in specific clinical situations; however, drug-coated variants are increasingly becoming the preferred choice among healthcare providers.

Hospitals Remain Primary End-users

Hospitals are expected to account for the largest share of the global cutting angioplasty balloons market throughout the forecast period. These institutions possess the infrastructure, specialized personnel, and advanced diagnostic capabilities required to perform complex cardiovascular procedures.

Patients often prefer hospitals for angioplasty treatments due to their reputation for safety, comprehensive care, and access to cutting-edge medical technologies. Furthermore, large patient volumes enable hospitals to invest in advanced interventional cardiology equipment and participate in clinical research initiatives.

Cardiac centers also contribute significantly to market demand, particularly in developed healthcare systems where specialized cardiovascular treatment facilities are expanding rapidly.

Regional Outlook

North America is anticipated to maintain its dominant position in the global cutting angioplasty balloons market through 2031. The region benefits from a high prevalence of cardiovascular diseases, advanced healthcare infrastructure, favorable reimbursement policies, and strong adoption of innovative medical technologies. The United States remains the largest contributor to regional revenue.

Meanwhile, Asia Pacific is expected to emerge as the fastest-growing regional market. Rising healthcare expenditure, increasing awareness of cardiovascular health, expanding healthcare infrastructure, and growing adoption of minimally invasive procedures are supporting market growth across countries such as China, India, and Japan.

China continues to experience strong demand due to its rapidly aging population and increasing incidence of heart disease. In India, investments in healthcare modernization and improved access to advanced cardiovascular treatments are creating significant growth opportunities. Japan's technologically advanced healthcare system is also contributing to regional expansion.

Competitive Landscape and Future Prospects

The cutting angioplasty balloons market is highly competitive, with leading companies focusing on product innovation, strategic partnerships, and geographic expansion. Major market participants include Abbott, Boston Scientific Corporation, B. Braun Melsungen AG, Cook Medical, Cordis, Medtronic, MicroPort Scientific Corporation, Opto Circuits (India) Ltd., Spectranetics (Philips Healthcare), Terumo Corporation, TriReme Medical, LLC, and Vascular Concepts Limited.

Although higher device costs compared to conventional angioplasty balloons remain a challenge, manufacturers are actively working to optimize production processes and improve supply chain efficiency. These efforts are expected to enhance affordability and expand adoption, particularly in emerging economies.

With increasing demand for advanced cardiovascular interventions and continued technological innovation, the global cutting angioplasty balloons market is well-positioned for sustained growth through 2031.